Faculty, Staff and Student Publications
Publication Date
1-8-2024
Journal
American Journal of Hematology
DOI
10.1016/j.ccell.2023.12.009
PMID
38194911
Abstract
Neoadjuvant chemotherapy plus immunotherapy for triple-negative breast cancer (TNBC) is associated with improved but incomplete response. In this issue of Cancer Cell, Shiao et al. characterize longitudinal biopsies from a window of opportunity study with single-cell RNA sequencing (scRNA-seq) and spatial proteomic profiling and elucidate synergy between radiotherapy (RT) and pembrolizumab.
Keywords
Humans, Radioimmunotherapy, Triple Negative Breast Neoplasms, Neoadjuvant Therapy, Patient Selection, Proteomics, Tumor Microenvironment
Published Open-Access
yes
Recommended Citation
Simona F Shaitelman and Wendy A Woodward, "Polatuzumab Vedotin, Venetoclax, and an Anti-CD20 Monoclonal Antibody in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma" (2024). Faculty, Staff and Student Publications. 5002.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/5002
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Genetic Phenomena Commons, Medical Genetics Commons, Oncology Commons